Kailera Therapeutics (KLRA.US), a newcomer in the weight-loss drug sector, began trading on the U.S. stock market on Friday, surging more than 50% at the opening to $24.1 per share, compared with its IPO price of $16. The company has set a record for the largest biotechnology IPO in the U.S. since 2021. Founded in 2024, Kailera is a late-stage clinical biotech firm developing four GLP-1-based weight-loss treatments. These include a once-weekly injectable and a once-daily oral pill, both of which have advanced to late-stage clinical trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments